153403-53-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-6-fluorobenzo[d]oxazole is used as a key intermediate in the synthesis of various biologically active compounds, including potential drugs. Its unique structure allows for the development of new pharmaceuticals with improved efficacy and selectivity.
Used in Agrochemical Industry:
This chemical compound is also utilized in the synthesis of agrochemicals, contributing to the development of novel pesticides and herbicides with enhanced performance and reduced environmental impact.
Used in Materials Science:
Research is ongoing to explore the potential applications of 2-Chloro-6-fluorobenzo[d]oxazole in materials science, where its unique properties may contribute to the development of advanced materials with specific characteristics.
Used in Organic Synthesis:
2-Chloro-6-fluorobenzo[d]oxazole serves as a versatile building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications across various industries.

Upstream product

• 145096-57-7 6-fluorobenzo[d]oxazole-2(3H)-thione 
• 53981-24-1 2-amino-5-fluorophenol 
• 145096-57-7 6-fluoro-1,3-benzoxazole-2-thiol 

Downstream Products

• 1147871-54-2 C₁₈H₂₆FN₃O₃S 
• 1334386-21-8 (R)-2-(6-fluorobenzoxazol-2-ylamino)-3-tritylsulfanyl-propionic acid 
• 1374820-09-3 C₁₇H₁₆Cl₂FN₃O 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

Preparation, antibacterial evaluation and preliminary structure-activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives

In this study, a novel benzothiazol- and benzooxazol-2-amine scaffold with antibacterial activity was designed and synthesized. Preliminary structure-activity relationship analysis displayed that compound 8t with a 5,6-difluorosubstituted benzothiazole was found to be a potent inhibitor of Gram-positive pathogens, and exhibited some potential against drug-resistant bacteria and without cytotoxicity in therapeutic concentrations. In addition, molecular docking studies indicated that Staphylococcus aureus methionyl-tRNA synthetase might be the possible target of these compounds. Taken together, the present study provides an effective entry to the synthesis of a good lead for subsequent optimization and a new small molecule candidate drug for antibacterial therapeutics.

Analgesic Compounds, Compositions, and Uses Thereof

The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.

Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists

A combination of benzoxazole, phenoxyalkyl side chain, and phenoxybutyric acids was identified as a highly potent and selective human peroxisome proliferator-activated receptor α (PPARα) agonist. The synthesis, structure-activity relationship (SAR) studies, and in vivo activities of the representative compounds are described.

Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: Heterocyclic P3

A series of Nα-2-benzoxazolyl-α-amino acid-(arylaminoethyl)amides were identified as potent, selective, and noncovalent inhibitors of cathepsin S. Structure-activity relationships including strategies for modulating the selectivities among cathepsins S, K, and L, and in vivo pharmacokinetics are discussed. A X-ray structure of compound 3 bound to the active site of cathepsin S is also reported.